| Literature DB >> 33200284 |
Ali Alsalme1, T Pooventhiran2, Nabil Al-Zaqri1, D Jagadeeswara Rao3, Siriki Srinivasa Rao4, Renjith Thomas5.
Abstract
HER-2 type breast cancer is one of the most aggressive malignancies found in women. Tucatinib is recently developed and approved as a potential medicine to fight this disease. In this manuscript, we present the gross structural features of this compound and its reactivity and wave function properties using computational simulations. Density functional theory was used to optimise the ground state geometry of the molecule and molecular docking was used to predict biological activity. As the electrons interact with electromagnetic radiations, electronic excitations between different energy levels are analysed in detail using time-dependent density functional theory. Various intermolecular and intermolecular interactions are analysed and reaction sites for attacking electrophiles and nucleophiles identified. Information entropy calculations show that the compound is inherently stable. Docking with COVID-19 proteins show docking score of - 9.42, - 8.93, - 8.45 and - 8.32 kcal/mol respectively indicating high interaction between the drug and proteins. Hence, this is an ideal candidate to study repurposing of existing drugs to combat the pandemic.Entities:
Keywords: DFT; Docking; LIE; NCI; Tucatinib
Mesh:
Substances:
Year: 2020 PMID: 33200284 PMCID: PMC7668570 DOI: 10.1007/s00894-020-04603-1
Source DB: PubMed Journal: J Mol Model ISSN: 0948-5023 Impact factor: 1.810
Fig. 1Geometry structure for tucatinib
Structural parameters of tucatinib
| Definition | Value (in Å) | Definition | Value (in °) |
|---|---|---|---|
| R(1O–12C) | 1.44 | A(12C–1O–15C) | 105.18 |
| R(1O–15C) | 1.36 | A(26C–2O–31C) | 118.20 |
| R(2O–26C) | 1.39 | A(11C–3N–15C) | 106.35 |
| R(2O–31C) | 1.36 | A(15C–4N–16C) | 127.74 |
| R(3N–11C) | 1.48 | A(15C–4N–45H) | 114.54 |
| R(3N–15C) | 1.28 | A(16C–4N–45H) | 117.67 |
| R(4N–15C) | 1.36 | A(21C–5N–23C) | 131.47 |
| R(4N–16C) | 1.39 | A(21C–5N–49H) | 114.73 |
| R(4N–45H) | 1.01 | A(23C–5N–49H) | 113.77 |
| R(5N–21C) | 1.37 | A(20C–6N–29C) | 115.19 |
| R(5N–23C) | 1.40 | A(21C–7N–29C) | 117.13 |
| R(5N–49C) | 1.01 | A(10N–8N–33C) | 110.27 |
| R(6N–20C) | 1.37 | A(10N–8N–35C) | 126.30 |
| R(6N–29C) | 1.31 | A(33C–8N–35C) | 123.43 |
| R(7N–21C) | 1.32 | A(33C–9N–36C) | 102.33 |
| R(7N–29C) | 1.36 | A(8N–10N–36C) | 101.28 |
| R(8N–10C) | 1.35 | A(1O–15C–3N) | 119.22 |
| R(8N–33C) | 1.38 | A(1O–15C–4N) | 112.02 |
| R(8N–35C) | 1.36 | A(3N–15C–4N) | 128.77 |
| R(9N–33C) | 1.33 | A(18C–17C–20C) | 120.68 |
| R(9N–36C) | 1.35 | A(18C–17C–21C) | 124.02 |
| R(10N–36C) | 1.33 | A(20C–17C–21C) | 115.29 |
| R(24C–30C) | 1.50 | A(5N–21C–7N) | 120.56 |
| R(26C–28C) | 1.39 | A(5N–21C–17C) | 118.20 |
| R(28C–52H) | 1.09 | A(7N–21C–17C) | 121.24 |
| R(31C–32C) | 1.37 | A(5N–23C–25C) | 124.34 |
| A(5N–23C–27C) | 116.38 | ||
| A(25C–23C–27C) | 119.28 | ||
| A(31C–32C–33C) | 117.93 | ||
| A(31C–32C–57H) | 122.84 | ||
| A(33C–32C–57H) | 119.23 | ||
| A(8N–33C–9N) | 109.08 | ||
| A(8N–33C–32C) | 118.91 | ||
| A(9N–33C–32C) | 132.01 |
Frontier molecular orbitals properties for tucatinib
| Property | Values |
|---|---|
| HOMO (eV) | − 5.59 |
| LUMO (eV) | − 1.59 |
| Energy gap ∆ | 4.00 |
| Ionisation energy ( | 5.59 |
| Electron affinity ( | 1.59 |
| Global hardness ( | 2.00 |
| Global softness ( | 0.50 |
| Chemical potential ( | − 3.59 |
| Electronegativity ( | 3.59 |
| Electrophilicity index ( | 3.22 |
| Nucleophilicity index ( | 0.31 |
| ∆ | 1.79 |
| Electroaccepting power | 0.31 |
| Electrodonating power | − 37.63 |
Fig. 2Simulated UV-Visible spectrum of tucatinib using TD-DFT CAM-B3LYP/cc-pVDZ
Fig. 3Major and minor contributions for tucatinib
Electronic transitions in tucatinib
| No. | Wavelength (nm) | Osc. Strength | Symmetry | Major contributions |
|---|---|---|---|---|
| 1 | 309.24 | 0.44 | Singlet-A | HOMO → LUMO (90%) |
| 2 | 267.56 | 0.26 | Singlet-A | H-2 → LUMO (12%), HOMO → |
| 3 | 265.44 | 0.0032 | Singlet-A | H-6 → LUMO (84%) |
Non-linear optics property for tucatinib
| Non-linear property | Tucatinib | Urea | Comparison of tucatinib with urea and | |
|---|---|---|---|---|
| Dipole moment ( | 2.74 D | 1.73 D | 0.91 D | 1.58 times urea and 3.01 times |
| Hyperpolarisability ( | 51.6*10−31 | 7.60*10−31 | 237.67*10−31 | 6.79 times urea and 0.21 times |
| Mean polarisability ( | 373.08*10−23 | 24.30*10−23 | 113.86*10−23 | 15.5 times greater than urea and 3.27 times PNA |
| Anisotropy of the polarisability (Δ | 897.38*10−23 | 0.85*10−23 | 5.29*10−23 | 1055 times greater than urea and 169 times PNA |
| Molar refractivity (MR) (esu) | 9412.26 | 613.31 | 2873.74 | 15.34 times greater than urea and 3.2 times PNA |
Fig. 4Average localised ionisation energy for tucatinib
Fig. 5Electron localised functions for tucatinib
Fig. 6Localised orbital location for tucatinib
Fig. 7Molecular electrostatic potentials for tucatinib
Fig. 8Molecular electrostatic potentials from nuclear charges for tucatinib
Fig. 9Reduced density gradient for tucatinib
Fig. 10Local information entropy for tucatinib
Fig. 11Non-covalent interactions for tucatinib
Docking result for tucatinib with coronovirus2 proteins
| Parameters | 6LU7 | 6W63 | 6M03 | 6LGZ |
|---|---|---|---|---|
| Energy | 58.0421 kcal/mol | 54.9743 kcal/mol | 60.3017 kcal/mol | 61.3409 kcal/mol |
| Simple fitness | 58.0421 kcal/mol | 54.9743 kcal/mol | 60.3017 kcal/mol | 61.3409 kcal/mol |
| Full fitness | − 1276.2 kcal/mol | − 1238.6 kcal/mol | − 1243 kcal/mol | − 3497.5 kcal/mol |
| Interfull fitness | − 68.14 kcal/mol | − 58.674 kcal/mol | − 59.893 kcal/mol | − 62.734 kcal/mol |
| Intrafull fitness | 11.7314 kcal/mol | 5.60706 kcal/mol | 9.84711 kcal/mol | 9.53814 kcal/mol |
| Solvent full fitness | − 1439 kcal/mol | − 1405.4 kcal/mol | − 1413.6 kcal/mol | − 3978 kcal/mol |
| Surface full fitness | 219.201 kcal/mol | 219.847 kcal/mol | 220.597 kcal/mol | 533.718 kcal/mol |
| Extra full fitness | 0 kcal/mol | 0 kcal/mol | 0 kcal/mol | 0 kcal/mol |
| Δ | − 1439 kcal/mol | − 1405.4 kcal/mol | − 1413.6 kcal/mol | − 3978 kcal/mol |
| Δ | 219.201 kcal/mol | 219.847 kcal/mol | 220.597 kcal/mol | 533.718 kcal/mol |
| Δ | − 1411.4 kcal/mol | − 1372.1 kcal/mol | − 1385.7 kcal/mol | − 3956.8 kcal/mol |
| Δ | 221.095 kcal/mol | 222.123 kcal/mol | 221.3 kcal/mol | 533.989 kcal/mol |
| Δ | − 62.539 kcal/mol | − 61.961 kcal/mol | − 64.017 kcal/mol | − 63.078 kcal/mol |
| Δ | 10.0198 kcal/mol | 9.94932 kcal/mol | 9.90626 kcal/mol | 9.90859 kcal/mol |
| Δ | − 68.14 kcal/mol | − 58.674 kcal/mol | − 59.893 kcal/mol | − 62.734 kcal/mol |
| Δ | 0 kcal/mol | 0 kcal/mol | 0 kcal/mol | 0 kcal/mol |
| Total Δ | − 9.4248 kcal/mol | − 8.9381 kcal/mol | − 8.4504 kcal/mol | − 8.3247 kcal/mol |
Fig. 12Skeletal structure of interactions between tucatinib and coronovirus2 proteins
Non-bond interactions label between coronovirus2 protein residues and tucatinib
| Non-bond interactions | Name of the coronovirus2 proteins | Labels of the coronovirus2 proteins |
|---|---|---|
| Hydrophobicity | 6LU7 | THR A:24, THR A:26, HIS A:41, CYS A:44, MET A:49, GLY A:143, CYS A:145, MET A:165 and GLN A:189 |
| 6W63 | HIS A:41, CYS A:44, SER A:46, MET A:49, LEU A:50, MET A:165, LEU A:167, PRO A:168, GLN A:189 and ALA A:191 | |
| 6M03 | PHE A:8, VAL A:104, ILE A:106, PHE A:112, ILE A:152, ASP A:153, SER A:158, PHE A:294, ASP A:295 and PHE A:305 | |
| 6LZG | LEU A:85, LYS A:94, LEU A:95, GLN A:98, GLN A:102, TYR A:196, GLU A:208, VAL A:209, ASN A:210 and ALA A:396 | |
| Hydrophilicity | 6LU7 | THR A:24, THR A:26, HIS A:41, ASN A:142, GLY A:143, HIS A:164, ASP A:187, ARG A:188 and GLN A:189 |
| 6W63 | HIS A:41, SER A:46, GLU A:166, PRO A:168, ASP A:187, ARG A:188, GLN A:189 and GLN A:192 | |
| 6M03 | LYS A:102, ARG A:105, GLN A:107, GLN A:110, GLN A:127, ASN A:151, ASP A:153, SER A:158 ASP A:295 and ARG A:298 | |
| 6LZG | LYS A:94, GLN A:98, GLN A:102, TYR A:196, ASP A:206, GLU A:208, ASN A:210, ARG A:219, ASN A:397, LYS A:562 and GLU A:564 | |
| Neutral groups | 6LU7 | THR A:24, THR A:25, THR A:26, THR A:45, SER A:46, GLY A:143 and SER A:144 |
| 6W63 | THR A:45, SER A:46, PRO A:168, THR A:169, GLY A:170 and THR A:190 | |
| 6M03 | THR A:111, SER A:158 and THR A:292 | |
| 6LZG | TYR A:196, GLY A:205, PRO A:565 and TRP A:566 | |
| Acidic groups | 6LU7 | ASP A:187 |
| 6W63 | GLU A:166 and ASP A:187 | |
| 6M03 | ASP A:153 and ASP A:295 | |
| 6LZG | ASP A:206, GLU A:208 and GLU A:564 | |
| Basic groups | 6LU7 | HIS A:41, HIS A:164 and ARG A:188 |
| 6W63 | HIS A:41 and ARG A:188 | |
| 6M03 | LYS A:102, ARG A:105 and ARG A:298 | |
| 6LZG | LYS A:94, ARG A:219 and LYS A:562 |